MedTrace Logo

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

NCT02693171 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2019-08-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.

Conditions

Interventions

DRUG

Dinutuximab

Unituxin was administered along with cytokines according to the prescribing information

Sponsors & Collaborators

  • United Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ami Desai, MD · Children's Hospital of Philadelphia

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-15
Primary Completion
2016-12-19
Completion
2016-12-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02693171 on ClinicalTrials.gov